Massively Parallel Sequencing: Making the MPS Vision an Everyday Reality

19 July 2017

Massively parallel sequencing (MPS) has become increasingly popular among forensic genomics laboratories. However, there are some challenges to implementation. Experts in the field of forensic genomics address these concerns and discuss the many benefits of MPS in everyday casework. A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. *Data calculations on file. Illumina, Inc., 2015. Subscribe to the Illumina video channel View customer spotlight videos View Illumina webinars View Illumina product videos View Illumina support videos

Share this article on